With Lumasiran Pediatric Data, Alnylam Hopes For Approvals In All PH1 Patients

 
• By Joseph Haas
Kidney healthcare, doing medical research
Alnylam waits for US and EU regulatory decisions in rare kidney disorder

More from Clinical Trials

More from R&D